The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)
Key facts
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Where
- Denmark2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 352 people enrolled
- Started
- 1 May 2021
- Expected to end
- 1 Apr 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rivaroxaban
- Acetylsalicylic acid
- Clopidogrel
- Edoxaban
- Dabigatran
- Apixaban
- Warfarin
- Record updated
- 6 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients who underwent successful TAVI according to Valve Academic Research Consortium (VARC)-2 criteria
- Residing in Denmark
- Provided written informed consent
Who cannot take part
- Atrial fibrillation or any other indication for lifelong oral anticoagulant therapy
- Patient deemed not suitable for DOAC treatment because of previous life-threatening or major bleeding, e.g. intracranial haemorrhage or major gastrointestinal bleeding
- Patient with absolute indication for anti-thrombotic therapy, e.g. recent PCI
- Iodine contrast allergy or other condition that prohibits CT imaging
- Patients with severe renal insufficiency (eGFR <30 mL/min/1.73 m2)
- Age <18 years
- Women of childbearing potential, pregnant or nursing
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized clinical trial investigating the incidence and temporal dynamics of subclinical leaflet thickening by cardiac CT in transcatheter bioprosthetic aortic valves in patients randomised to different anti-thrombotic strategies. Additionally, this study aims to examine a possible association between HALT and thromboembolic events.
The 2 groups in the trial
- Sinus rhythm - DOAC treatmentTreatment being tested
Can either of the following anti-platelet components: dabigatran, apixaban, rivaroxaban, edoxaban or warfarin. Duration: 3 months, followed by an anti-platelet hereafter.
Treatment: Rivaroxaban, Edoxaban, Dabigatran, Apixaban, and Warfarin
- Sinus rhythm - Anti-platelet treatmentExisting treatment, for comparison
Can be either of the following anti-platelet components: acetylsalicylic acid or clopidogrel. Duration: Lifelong
Treatment: Acetylsalicylic acid and Clopidogrel
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Study on the Impact of Different Anti-thrombotic Therapies on Subclinical Leaflet Thickening and Its Temporal Dynamics in Transcatheter Bioprosthetic Aortic Valves (NOTION-4)
- Publications
- Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial.Journal of the American College of Cardiology, 2026
- Prospective study on the impact of different antithrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves-The NOTION-4 trial.American heart journal, 2025
- Record updated
- 6 April 2025